Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    Cirmtuzumab
Previous Study | Return to List | Next Study

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02776917
Recruitment Status : Recruiting
First Posted : May 18, 2016
Last Update Posted : March 29, 2019
Sponsor:
Collaborator:
Oncternal Therapeutics, Inc
Information provided by (Responsible Party):
Barbara Parker, MD, University of California, San Diego

Brief Summary:
This is a pilot phase 1b study to investigate the safety and side effects of combining the ROR1-targeting monoclonal antibody, cirmtuzumab, with paclitaxel for patients with HER2 negative, metastatic breast cancer. Cirmtuzumab is a type of drug called a monoclonal antibody. This drug is designed to attach to a protein called receptor-tyrosine-kinase like orphan receptor 1 (ROR1) on the surface of breast cancer cells. Cirmtuzumab blocks the growth and survival of the breast cancer cells in laboratory tests. ROR1 is rarely expressed on healthy cells. Cirmtuzumab is considered experimental and is not approved by United States (U.S.) Food and Drug Administration (FDA).

Condition or disease Intervention/treatment Phase
Breast Neoplasms Drug: Cirmtuzumab + Paclitaxel Phase 1

Detailed Description:
  • This is a phase 1b, open-label, non-randomized, fixed dose study in patients with HER2 negative metastatic, or locally advanced, unresectable breast cancer.
  • Cirmtuzumab and paclitaxel will be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity, as long as the subject is tolerating the drug and does not exhibit disease progression.
  • Blood and tissue samples will be collected at pre-specified times to enable pharmacokinetic and correlative studies.
  • Adverse events (AE) will be monitored throughout the trial. Reporting of AEs will be in accordance with CTCAE version 4.03.
  • Assessment of tumor response will be performed by physical examination and/or by radiographic imaging and according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
  • Patients will be assessed at 28 days following the last dose of cirmtuzumab to assess tumor response and at 56 days following the last dose of cirmtuzumab to assess any adverse events and to document any concomitant cancer therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer
Actual Study Start Date : August 15, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Cirmtuzumab + Paclitaxel

Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle.

Drug: Cirmtuzumab + Paclitaxel
Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
Other Name: UC-961, Taxol




Primary Outcome Measures :
  1. The rate of dose-limiting toxicities during the first 4 weeks of treatment [ Time Frame: Within 4 weeks of starting study treatment ]
    The proportion of clinically significant adverse events per CTCAE Version 4.03 at least possibly related to cirmtuzumab or the combination of cirmtuzumab and paclitaxel during the first four weeks of investigational treatment.


Secondary Outcome Measures :
  1. Safety and tolerability of the combination therapy since the start of any study treatment. [ Time Frame: 12 months ]
    Treatment-emergent adverse events beginning from the start of study treatment to six months after study treatment completion.

  2. Objective tumor response rate [ Time Frame: 9 months ]
    The proportion of patients with complete and partial tumor responses as assessed by RECIST v1.1

  3. Best tumor response rate [ Time Frame: 9 months ]
    The proportion of patients that achieve a response of stable disease or better as assessed by RECIST v1.1

  4. Time to progression [ Time Frame: 2 years ]
    The duration of response measured from the time of initial response until documented tumor progression.

  5. Measurement of ROR1 expression levels and cancer stem cell populations [ Time Frame: 12 months ]
    Immunohistochemistry measurement of ROR1 expression levels and other cancer stem cell markers (ALDH, CD133) from primary pre-treatment and post-treatment tumor specimens.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Biopsy-confirmed, metastatic or locally advanced surgically unresectable, HER2 negative breast cancer. HER2 status should reflect the most recent biopsy results. Note: HER2 negative breast cancer is defined according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines 2013 for HER2 testing performed in a CLIA-certified laboratory.
  • ER/PR negative (<10% of cells staining for ER or PR) breast cancer or have ER/PR positive (≥10% of cells staining for ER or PR) breast cancer that has exhausted standard endocrine therapy and/or in the opinion of the treating oncologist, warrants cytotoxic chemotherapy.
  • Measurable disease as defined by RECIST v1.1. Measurable lesions will be confirmed by radiographic imaging (CT or MRI). Patients with bone only disease will be eligible if disease is considered measurable and a soft tissue component is present and can be biopsied..
  • There is no limit to prior lines of therapy, but patients must not have received prior taxane chemotherapy in the metastatic setting.
  • ECOG Performance Status ≤ 2.
  • Adequate organ function as defined below:

    • Absolute Neutrophil Count ≥ 1.0 x 10^9/L
    • Platelet count ≥ 100,000 /μL
    • Hemoglobin ≥ 8.0 g/dL
    • Total bilirubin ≤ 1.5 x upper limit of normal
    • AST and ALT ≤ 3 x upper limit of normal
    • Serum creatinine ≤ 2 x upper limit of normal OR Creatinine clearance > 40 ml/min/1.73 m^2
  • Women of child-bearing potential and male subjects who are sexually active with a woman of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months following last infusion of cirmtuzumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Existing neuropathy must be no greater than Grade 1.
  • No concurrent antibody therapy can be planned with the exception of denosumab for use in bone metastasis.
  • CNS metastases are allowed as long as the metastases are asymptomatic, have been treated with radiation, and have been stable for > 6 weeks off steroids.

EXCLUSION CRITERIA:

  • Patient is currently receiving chemotherapy or has received another chemotherapy within 5 half-lives, radiotherapy or immunotherapy within 2 weeks prior to study treatment initiation.
  • Patient has known, untreated and/or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Patient had disease that was refractory to paclitaxel in the neoadjuvant setting and/or developed metastatic breast cancer within 6 months of neoadjuvant or adjuvant taxane chemotherapy.
  • Patient has had major surgery within 3 weeks prior to enrollment.
  • Patient has severe and/or uncontrolled medical disease(s) (i.e., myocardial infarction within 6 months of study, CKD stage IV or above, severe chronic pulmonary disease or active infection).
  • The patient has known acute or chronic hepatitis B or C.
  • The patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel.
  • The patient has a history of another malignancy within 2 years prior to study entry, except curatively treated non-melanotic skin cancer, cervical carcinoma in situ or stage I colon cancer.
  • Patient has a history of non-compliance or other medical illness that would preclude compliance with study procedures.
  • Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient has severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable cardiac or coronary artery disease
  • Patient is pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02776917


Contacts
Layout table for location contacts
Contact: Barbara Parker, MD 858-822-6135 baparker@ucsd.edu
Contact: Rebecca Shatsky, MD 858-657-7000 rshatsky@ucsd.edu

Locations
Layout table for location information
United States, California
University of California, San Diego Recruiting
La Jolla, California, United States, 92093
Contact: Jillian McCarthy, MPH    858-822-4516    jmccarthy@ucsd.edu   
Sponsors and Collaborators
Barbara Parker, MD
Oncternal Therapeutics, Inc
Investigators
Layout table for investigator information
Principal Investigator: Barbara Parker, MD University of California, San Diego

Layout table for additonal information
Responsible Party: Barbara Parker, MD, Clinical Professor of Medicine, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02776917     History of Changes
Other Study ID Numbers: 160178
First Posted: May 18, 2016    Key Record Dates
Last Update Posted: March 29, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Barbara Parker, MD, University of California, San Diego:
metastatic breast cancer
locally advanced, unresectable breast cancer
HER2/NEU negative

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action